MedTrace Logo

An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization

NCT04729140 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-04-01

No results posted yet for this study

Summary

The purpose of this Clinical trial is to explore the therapeutic benefits of Ivermectin and Doxycycline in different combinations in high risk patients diagnosed with COVID-19.

Conditions

  • Covid19

Interventions

DRUG

Ivermectin Tablets

Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.

DRUG

Doxycycline Tablets

Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.

DRUG

Placebo

Double-blinded, prospective, placebo controlled outpatient randomized clinical trial.

Sponsors & Collaborators

  • Max Health, Subsero Health

    lead OTHER

Principal Investigators

  • Werther Marciales, MD · Clinical Trial Principal Investigator

  • Ryan Salom · sub Clinical Trial Prinicipal Investigator

  • Faheem Ahmad, MD · sub Clinical Trial Prinicipal Investigator

  • Divisha Sharma, MD · Clinical Trial Investigator

  • Nicholas Guy Ross, DO · Clinical Trial Investigator

  • Terry Fredeking · Clinical Trial Investogator

  • Michael Ricciardi, PhD · Clinical Trial Investogator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-28
Primary Completion
2021-12-28
Completion
2022-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729140 on ClinicalTrials.gov